Syed Ali-aamir Rizvi
Known title: Chief Medical OfficerCIK: 0001897621
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
No recent news for Caribou Biosciences (CRBU). There are no recent news releases specifically about Caribou Biosciences in the past week. The stock remains unchanged in terms of public announcements. Technical indicators show RSI at 35.1 and support around $1.59, but without new information the market context is limited.
Transaction History
| RCKT | ▲ Buy | Grant | 61,963 | $0 | 2/11/2026 | View on chart |
| RCKT | ▲ Buy | Grant | 283,018 | $0 | 10/6/2025 | View on chart |
| RCKT | ▲ Buy | Grant | 62,893 | $0 | 10/6/2025 | View on chart |
| CRBU | ▼ Sell | Open Market | 5,627 | $36K | 1/19/2023 | View on chart |
| CRBU | ▲ Buy | Grant | 60,000 | $0 | 1/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial
Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial. Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.